Showing results (21-30 of 50) with videos related to

Sort By:
Pageof 5
Clinical Pharmacokinetics|July 10, 2002
Elimination of stabilised hyaluronan from the knee joint in healthy menUlla Lindqvist, Vladimir Tolmachev, Kalevi Kairemo, et al.
Clinical Physiology and Functional Imaging|April 11, 2012
Evaluating abdominal oedema during experimental sepsis using an isotope techniqueMarco Lattuada, Enn Maripuu, Carl Hard af Segerstad, et al.
European Journal of Nuclear Medicine and Molecular Imaging|May 12, 2009
The influence of Bz-DOTA and CHX-A''-DTPA on the biodistribution of ABD-fused anti-HER2 Affibody molecules: implications for (114m)In-mediated targeting therapyVladimir Tolmachev, Helena Wållberg, Karl Andersson, et al.
Cancer Biotherapy & Radiopharmaceuticals|September 7, 2007
Biodistribution of 211At-labeled humanized monoclonal antibody A33Ylva Almqvist, Ann-Charlott Steffen, Hans Lundqvist, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|October 9, 2002
110mIn-DTPA-D-Phe1-octreotide for imaging of neuroendocrine tumors with PETMark Lubberink, Vladimir Tolmachev, Charles Widström, et al.
Nuclear Medicine and Biology|March 12, 2004
Radiobromination of monoclonal antibody using potassium [76Br] (4 isothiocyanatobenzyl-ammonio)-bromo-decahydro-closo-dodecaborate (Bromo-DABI)Alexander Bruskin, Igor Sivaev, Mikael Persson, et al.
Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine|April 2, 2010
Blocking EGFR in the liver improves the tumor-to-liver uptake ratio of radiolabeled EGFHeewa Kareem, Karl Sandström, Ronny Elia, et al.
Nuclear Medicine and Biology|March 30, 2010
In vivo binding of [68Ga]-DOTATOC to somatostatin receptors in neuroendocrine tumours--impact of peptide massIrina Velikyan, Anders Sundin, Barbro Eriksson, et al.
Pageof 5